Company Overview - Corvus Pharmaceuticals (NASDAQ:CRVS) is a small biotech company focused on developing innovative treatments for various medical conditions, particularly eczema [1] - The company has a market capitalization of approximately $1.36 billion, reflecting its growing presence in the biotech industry [4][5] Stock Performance - The stock price of CRVS is currently at $18.20, marking a significant increase of 126.09% with a change of $10.15 [3] - The stock has fluctuated between a low of $12.69 and a high of $19.12 today, with $19.12 being its highest price for the year [3] - Recently, the stock reached an eight-year high following the release of promising eczema treatment results [2][5] Analyst Insights - Sean Lee from H.C. Wainwright set a new price target of $27 for CRVS, indicating a potential increase of approximately 48.19% from its current trading price of $18.22 [2][5] - The trading volume for the day is 54.94 million shares, indicating strong investor interest and confidence in the company's potential impact in the biotech sector [4][5]